Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.48 |
| ▸ | DRD3 | P35462 | 9/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4515655 | 0.85 | SMN1; SMN2 (0.54) | DRD2DRD3GAAMAPTSMN1; SMN2 | |
| SCHEMBL4516920 | 0.85 | MAPT (0.56) | DRD2DRD3HTR7MAPTSMN1; SMN2 | |
| SCHEMBL13757755 | 0.84 | GPR119 (0.58) | MAPTGPR119 | |
| SCHEMBL6073687 | 0.83 | GPR119 (0.50) | KDM4EGAAMAPTGFERGPR119 | |
| SCHEMBL30919728 | 0.81 | CHRM4 (0.45) | DRD2MAPTGPR119 | |
| SCHEMBL30981429 | 0.76 | KCNA3 (0.54) | DRD2DRD3KDM4EGAAMAPT | |
| SCHEMBL14624178 | 0.76 | DRD2 (0.47) | DRD2DRD3HTR7KDM4EGAA | |
| SCHEMBL31334279 | 0.76 | CHRM4 (0.42) | DRD2DRD3GAAMAPTGFER | |
| SCHEMBL4487038 | 0.75 | DRD2 (0.57) | DRD2DRD3HTR7MAPT | |
| SCHEMBL3847014 | 0.75 | DRD2 (0.59) | DRD2DRD3HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| EP-1909791-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007003964-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | GPR119, GCGR, GPBAR1 | DRD2 1031/4885DRD3 1081/4885HTR7 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.